プラダーウィリ症候群治療の世界市場2018-2022...市場調査レポートについてご紹介

【英文タイトル】Global Prader-Willi Syndrome Therapeutics Market 2018-2022

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: PIPELINE LANDSCAPE
PART 08: MARKET SEGMENTATION BY PRODUCT
• Segmentation by product
• Comparison by product
• Recombinant growth hormones – Market size and forecast 2017-2022
• Others – Market size and forecast 2017-2022
• Market opportunity by product
• CUSTOMER LANDSCAPE
PART 09: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
• Strong pipeline
• Increasing strategic alliances
• Use of advanced technologies for diagnosis and treatment of PWS
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Eli Lilly and Company
• Novartis
• Novo Nordisk
• Pfizer
PART 15: APPENDIX
• List of abbreviations



Exhibit 01: Parent market
Exhibit 02: Global rare disease therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition: Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global – Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2017
Exhibit 18: Pipeline landscape by development phase 2017-2018
Exhibit 19: Key clinical trial candidates for treatment of PWS
Exhibit 20: Global PWS therapeutics market by product 2017-2022 (%)
Exhibit 21: Comparison by product
Exhibit 22: Recombinant growth hormones – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Recombinant growth hormones – Year-over-year growth 2018-2022 (%)
Exhibit 24: Others – Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Others – Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Global – Market share by geography 2017-2022 (%)
Exhibit 29: Regional comparison
Exhibit 30: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 31: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 32: Top 3 countries in Americas
Exhibit 33: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 34: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 35: Top 3 countries in EMEA
Exhibit 36: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 37: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 38: Top 3 countries in APAC
Exhibit 39: Market opportunity
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Eli Lilly and Company – Overview
Exhibit 46: Eli Lilly and Company – Business segments
Exhibit 47: Eli Lilly and Company – Organizational developments
Exhibit 48: Eli Lilly and Company – Geographic focus
Exhibit 49: Eli Lilly and Company – Segment focus
Exhibit 50: Eli Lilly and Company – Key offerings
Exhibit 51: Eli Lilly and Company – Key customers
Exhibit 52: Novartis – Overview
Exhibit 53: Novartis – Business segments
Exhibit 54: Novartis – Organizational developments
Exhibit 55: Novartis – Geographic focus
Exhibit 56: Novartis – Segment focus
Exhibit 57: Novartis: Key offerings
Exhibit 58: Novartis – Key customers
Exhibit 59: Novo Nordisk – Overview
Exhibit 60: Novo Nordisk – Business segments
Exhibit 61: Novo Nordisk – Organizational developments
Exhibit 62: Novo Nordisk – Geographic focus
Exhibit 63: Novo Nordisk – Segment focus
Exhibit 64: Novo Nordisk – Key offerings
Exhibit 65: Novo Nordisk – Key customers
Exhibit 66: Pfizer – Overview
Exhibit 67: Pfizer – Business segments
Exhibit 68: Pfizer – Organizational developments
Exhibit 69: Pfizer – Geographic focus
Exhibit 70: Pfizer – Segment focus
Exhibit 71: Pfizer – Key offerings
Exhibit 72: Pfizer – Key customers


【レポート販売概要】

■ タイトル:プラダーウィリ症候群治療の世界市場2018-2022
■ 英文:Global Prader-Willi Syndrome Therapeutics Market 2018-2022
■ 発行日:2018年11月28日
■ 調査会社:Technavio
■ 商品コード:IRTNTR23589
■ 調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。